Lipid-lowering drugs acting at the level of the gastrointestinal tract

Current Pharmaceutical Design

Volumn 15, Issue 5, 2009, Pages 490-516

  Filippatos, T D ^a   Mikhailidis, D P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Colesevelam; Colestimide; Colestipol; Colestyramine; Ezetimibe; Low density lipoprotein cholesterol; Orlistat; Phytosterols

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FRUCTOSAMINE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; STANOL ESTER; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VALPROIC ACID; VITAMIN; ANTIOBESITY AGENT; AZETIDINE DERIVATIVE; BILE ACID; HYPOCHOLESTEROLEMIC AGENT; LACTONE;

ADD ON THERAPY; ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; DRUG EFFECT; METABOLISM;

ANIMALS; ANTI-OBESITY AGENTS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BILE ACIDS AND SALTS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL TRACT; HUMANS; LACTONES; PHYTOSTEROLS;

EID: 64749115172     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787315738     Document Type: Review

References (450)

1. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
4. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
5. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
6. Buchwald H, Varco RL, Boen JR, Williams SE, Hansen BJ, Campos CT, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998; 158: 1253-61.
7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
8. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D, et al. Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991; 40 Suppl 1: S53-8.
9. Packard CJ, Shepherd J. The hepatobiliary axis and lipoprotein metabolism: Effects of bile acid sequestrants and ileal bypass surgery. J Lipid Res 1982; 23: 1081-98.
10. Grundy SM, Ahrens EH, Jr., Salen G. Interruption of the enterohepatic circulation of bile acids in man: Comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78: 94-121.
11. Shepherd J, Packard CJ, Bicker S, Lawrie TD, Morgan HG. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980; 302: 1219-22.
12. Robins SJ, Fasulo JM. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J Clin Invest 1997; 99: 380-4.
13. Insull W, Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review. South Med J 2006; 99: 257-73.
14. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: Is now a good time to remember? Am J Ther 2007; 14: 567-80.
15. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002; 109: 961-71.
16. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-18.
17. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: A review. Expert Opin Pharmacother 2007; 8: 2569-78.
18. Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol 1990; 30: 99-106.
19. Aldridge MA, Ito MK. Colesevelam hydrochloride: A novel bile acid-binding resin. Ann Pharmacother 2001; 35: 898-907.
20. Takeuchi A, Sano N, Takikawa H. Inhibition of ileal bile acid absorption by colestimide. J Gastroenterol Hepatol 2003; 18: 548-53.
21. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007; 54: 53-8.
22. Tasaki H, Miyamoto M, Kubara T, Kamezaki F, Tanaka S, Yamashita K, et al. Cross-over trial of intensive monotherapy with atorvastatin and combined therapy with atorvastatin and colestimide for Japanese familial hypercholesterolemia. Circ J 2006; 70: 14-20.
23. Suzuki T, Oba K, Futami S, Suzuki K, Ouchi M, Igari Y, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: A case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006; 73: 277-84.
24. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
25. O'Brien RC, Simons LA, Clifton P, Cooper ME, Jennings GL, Jerums G, et al. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Med J Aust 1990; 152: 480-3.
26. Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson SO, Berglund L, et al. Treatment of familial hypercholesterolaemia: A controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 1990; 228: 241-7
27. Ros E, Zambon D, Bertomeu A, Cuso E, Sanllehy C, Casals E. Comparative study of a microporous cholestyramine analogue (filicol) and gemfibrozil for treatment of severe primary hypercholesterolemia. Short- and long-term results. Arch Intern Med 1991; 151: 301-5.
28. Ditschuneit HH, Dreyer M, Dammann HG, Ditschuneit H. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study]. Med Klin 1991; 86: 142-8 (Abstract).
29. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9.
30. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II. Arch Intern Med 1993; 153: 1321-9.
31. Hagen E, Istad H, Ose L, Bodd E, Eriksen HM, Selvig V, et al. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol 1994; 46: 445-9.
32. Eriksson M, Hadell K, Holme I, Walldius G, Kjellstrom T. Compliance with and efficacy of treatment with pravastatin and cholestyramine: A randomized study on lipid-lowering in primary care. J Intern Med 1998; 243: 373-80.
33. McPherson R. Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can J Clin Pharmacol 1999; 6: 85-90.
34. Insull W, Jr., Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial. Mayo Clin Proc 2001; 76: 971-82.
35. Donovan JM, Von Bergmann K, Setchell KD, Isaacsohn J, Pappu AS, Illingworth DR, et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 2005; 50: 1232-8.
36. Ericsson S, Berglund L, Frostegard J, Einarsson K, Angelin B. The influence of age on low density lipoprotein metabolism: Effects of cholestyramine treatment in young and old healthy male subjects. J Intern Med 1997; 242: 329-37.
37. Ebeling T, Turtola H, Voutilainen E, Uusitupa M, Pyorala K, Reijonen T. Comparison between lovastatin and cholestyramine in the treatment of moderate to severe primary hypercholesterolaemia. Ann Med 1992; 24: 121-7.
38. Betteridge DJ, Bhatnager D, Bing RF, Durrington PN, Evans GR, Flax H, et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992; 304: 1335-8.
39. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 313-24.
40. Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm 2002; 59: 932-9.
41. Fletcher GF, Fletcher BJ, Whitner JT, Staggers J, Almon L. Effects of variable doses and formulations of cholestyramine on elevated serum low-density lipoprotein cholesterol. Am J Cardiol 1995; 75: 738-9.
42. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 1893-900.
43. Superko HR, Greenland P, Manchester RA, Andreadis NA, Schectman G, West NH, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 1992; 70: 135-40.
44. Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol 1993; 71: 759-65.
45. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007; 67: 1383-92.
46. Duntsch G. [Colestipol by hypercholesteremia in diabetics]. Fortschr Med 1977; 95: 1492-6 (Abstract).
47. Bandisode MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res Clin Exp 1975; 18: 276-84.
48. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007; 56: 239-47.
49. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121: 416-22.
50. Schmidt EB, Illingworth DR, Bacon S, Mahley RW, Weisgraber KH. Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100. Atherosclerosis 1993; 98: 213-7.
51. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, Tselepis AD, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23: 1169-76.
52. Mikhailidis DP, Wierzbicki AS. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000; 16: 139-46.
53. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20: 1253-68.
54. Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: Impressions from the BIP and VA-HIT trials. Int J Cardiol 2002; 82: 199-207.
55. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C--the importance of raising HDL-C. Curr Med Res Opin 2002; 18: 36-44.
56. Kolovou GD, Mikhailidis DP, Anagnostopoulou KK, Daskalopoulou SS, Cokkinos DV. Tangier disease four decades of research: A reflection of the importance of HDL. Curr Med Chem 2006; 13: 771-82.
57. Duntsch G. [Long-term therapy of hypercholesteremia in diabetics with colestipol]. Fortschr Med 1981; 99: 73-5 (Abstract).
58. Lyons D, Webster J, Fowler G, Petrie JC. Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. Br J Clin Pharmacol 1994; 37: 59-62.
59. Korhonen T, Hannuksela ML, Seppanen S, Kervinen K, Kesaniemi YA, Savolainen MJ. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment. Eur J Clin Pharmacol 1999; 54: 903-10.
60. Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007; 99: 47C-55C.
61. Klosiewicz-Latoszek L, Nowicka G, Szostak WB. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins]. Wiad Lek 1993; 46: 581-5 (Abstract).
62. Angelin B, Leijd B, Hultcrantz R, Einarsson K. Increased turnover of very low density lipoprotein triglyceride during treatment with cholestyramine in familial hypercholesterolaemia. J Intern Med 1990; 227: 201-6.
63. Levy RI, Brensike JF, Epstein SE, Kelsey SF, Passamani ER, Richardson JM, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 325-37.
64. Insull W, Jr., Davidson MH, Demke DM, Dujovne CA, Eckert SM, Ginsberg D, et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis 1995; 112: 223-35.
65. Linet OI, Grzegorczyk CR, Demke DM. The effect of encapsulated, low-dose colestipol in patients with hyperlipidemia. J Clin Pharmacol 1988; 28: 804-6.
66. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-28.
67. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007; 7: 53-72.
68. Witztum JL, Schonfeld G, Weidman SW. The effects of colestipol on the metabolism of very-low-density lipoproteins in man. J Lab Clin Med 1976; 88: 1008-18.
69. Young SG, Witztum JL, Carew TE, Krauss RW, Lindgren FT. Colestipol-induced changes in LDL composition and metabolism. II. Studies in humans. J Lipid Res 1989; 30: 225-38.
70. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006; 185: 327-30
71. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005; 51: 2264-73.
72. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006; 55: 885-91.
73. Tsimihodimos V, Gazi I, Kostara C, Tselepis AD, Elisaf M. Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids 2007; 42: 403-9.
74. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002; 22: 1175-80.
75. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255: 188-205.
76. Groot PH, Dijkhuis-Stoffelsma R, Grose WF, Ambagtsheer JJ, Fernandes J. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia. Acta Paediatr Scand 1983; 72: 81-5.
77. Mordasini R, Twelsiek F, Oster P, Schellenberg B, Raetzer H, Heuck CC, et al. Abnormal low density lipoproteins in children with familial hypercholesterolemia--effect of polyanion exchange resins. Klin Wochenschr 1978; 56: 805-8.
78. Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 1990; 39: 269-73.
79. Molgaard J, von Schenck H, Olsson AG. Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia. Eur J Clin Pharmacol 1989; 36: 455-60.
80. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III. JAMA 1988; 260: 359-66.
81. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia. Atherosclerosis 1982; 44: 61-71.
82. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: A new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 2008; 24: 995-1009.
83. Hunninghake DB, Stein EA, Bremner WF, Greenland P, Demke DM, Oliphant TH. Dose - Response Study of Colestipol Tablets in Patients with Moderate Hypercholesterolemia. Am J Ther 1995; 2: 180-189.
84. Schwartzkopff W, Bimmermann A, Schleicher J. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia]. Arzneimittelforschung 1990; 40: 1322-7 (Abstract).
85. Sonoyama K, Nishikawa H, Kiriyama S, Niki R. Cholestyramine and a fat-free diet lower apolipoprotein A-IV mRNA in jejunum and cholestyramine lowers apolipoprotein A-I mRNA in ileum of rats. J Nutr 1994; 124: 621-7.
86. Staels B, Van Tol A, Fruchart JC, Auwerx J. Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Isr J Med Sci 1996; 32: 490-8.
87. Sonoyama K, Nishikawa H, Kiriyama S, Niki R. Bile diversion lowers apolipoprotein A-I and A-IV mRNA levels in rat ileum. J Nutr Sci Vitaminol (Tokyo) 1994; 40: 343-52.
88. Sonoyama K, Nishikawa H, Kiriyama S, Niki R. Apolipoprotein mRNA in liver and intestine of rats is affected by dietary beet fiber or cholestyramine. J Nutr 1995; 125: 13-9.
89. Bard JM, Dallongeville J, Hagen E, Pfister P, Ose L, Fruchart JC, et al. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Metabolism 1995; 44: 1447-54.
90. Berglund L, Wiklund O, Eggertsen G, Olofsson SO, Eriksson M, Linden T, et al. Apolipoprotein E phenotypes in familial hypercholesterolaemia: Importance for expression of disease and response to therapy. J Intern Med 1993; 233: 173-8.
91. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000; 53: 487-96.
92. Milionis HJ, Filippatos TD, Loukas T, Bairaktari ET, Tselepis AD, Elisaf MS. Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 2006; 187: 170-6.
93. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771-4.
94. Ceska R, Sobra J, Toschnerova H, Traurig J. [Colestipol in the treatment of heterozygous familial hypercholesterolemia]. Cas Lek Cesk 1992; 131: 118-20 (Abstract).
95. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; 335: 1360-3.
96. Athyros VG, Mikhailidis DP, Kakafika AI, Karagiannis A, Hatzitolios A, Tziomalos K, et al. Identifying and attaining LDL-C goals: Mission accomplished? Next target: New therapeutic options to raise HDL-C levels. Curr Drug Targets 2007; 8: 483-8.
97. Miller M. Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy? Prev Cardiol 2007; 10: 31-5.
98. Nilsson LM, Abrahamsson A, Sahlin S, Gustafsson U, Angelin B, Parini P, et al. Bile acids and lipoprotein metabolism: Effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem Biophys Res Commun 2007; 357: 707-11.
99. Moore JD. Successful Treatment with Colesevelam HCl and Pravastatin in a Patient Previously Hospitalised with Severe Normal CPK Myopathy on Introduction of Simvastatin. Clin Drug Investig 2005; 25: 417-20.
100. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110: 352-60.
101. Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, et al. Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol. J Cardiovasc Pharmacol Ther 1996; 1: 117-122.
102. Gaw A, Packard CJ, Lindsay GM, Murray EF, Griffin BA, Caslake MJ, et al. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1996; 16: 236-49.
103. Barbir M, Hunt BJ, Galloway D, Taylor A, Ilsley C, Mitchell A, et al. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Clin Cardiol 1994; 17: 59-64.
104. Ito MK, Shabetai R. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. Am J Cardiol 1997; 80: 799-802.
105. Jacob BG, Richter WO, Schwandt P. Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia. J Cardiovasc Pharmacol 1993; 22: 396-400.
106. Jacob BG, Mohrle W, Richter WO, Schwandt P. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia. Eur J Clin Pharmacol 1992; 42: 353-8
107. Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990; 48: 201-7.
108. Ytre-Arne K, Nordoy A. Simvastatin and cholestyramine in the long-term treatment of hypercholesterolaemia. J Intern Med 1989; 226: 285-90.
109. Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120: 537-43.
110. Ballantyne CM, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial. Clin Ther 2004; 26: 1855-64.
111. Molgaard J, Lundh BL, von Schenck H, Olsson AG. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia. Atherosclerosis 1991; 91 Suppl: S21-8.
112. Erkelens DW. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology 1990; 77 Suppl 4: 33-8.
113. Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 1988; 73: 135-41.
114. Schrott HG, Stein EA, Dujovne CA, Davidson MH, Goris GB, Oliphant TH, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995; 75: 34-9.
115. Bard JM, Ose L, Hagen E, Duriez P, Pfister P, Fruchart JC, et al. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group. Am J Cardiol 1995; 76: 65A-70A.
116. Hunninghake D, Insull W, Jr., Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158: 407-16.
117. Malmendier CL, Delcroix C, Lontie JF. The effect of combined fenofibrate and cholestyramine therapy on low-density lipoprotein kinetics in familial hypercholesterolemia patients. Clin Chim Acta 1987; 162: 221-7.
118. Fischer S, Hanefeld M, Lang PD, Fucker K, Bergmann S, Gehrisch S, et al. Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia. Arzneimittelforschung 1990; 40: 469-72.
119. Series JJ, Caslake MJ, Kilday C, Cruickshank A, Demant T, Lorimer AR, et al. Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia. Metabolism 1989; 38: 153-8.
120. Curtis LD, Dickson AC, Ling KL, Betteridge J. Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia. BMJ 1988; 297: 173-5.
121. Sommariva D, Tirrito M, Bonfiglioli D, Pogliaghi I, Branchi A, Cabrini E. Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients. Int J Clin Pharmacol Res 1986; 6: 249-53.
122. Klosiewicz-Latoszek L, Nowicka G, Szostak WB, Naruszewicz M. Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia. Atherosclerosis 1987; 63: 203-9.
123. Weisweiler P. Low-dose colestipol plus fenofibrate: Effects on plasma lipoproteins, lecithin:cHolesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia. Metabolism 1989; 38: 271-4
124. Weisweiler P, Merk W, Jacob B, Schwandt P. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia. Eur J Clin Pharmacol 1986; 30: 191-4.
125. Klosiewicz-Latoszek L, Szostak WB. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Eur J Clin Pharmacol 1991; 40: 33-41.
126. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005; 21: 1403-12.
127. Xydakis AM, Guyton JR, Chiou P, Stein JL, Jones PH, Ballantyne CM. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004; 94: 795-7.
128. Knopp RH, Tsunehara C, Retzlaff BM, Fish B, Nguyen H, Anderson S, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: A pilot study. Metabolism 2006; 55: 1697-703.
129. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005; 12: 306-10.
130. Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006; 22: 2191-200.
131. Rivers SM, Kane MP, Busch RS, Bakst G, Hamilton RA. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007; 13: 11-6.
132. Salen G, Starc T, Sisk CM, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 2006; 130: 1853-7.
133. Series JJ, Gaw A, Kilday C, Bedford DK, Lorimer AR, Packard CJ, et al. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia. Br J Clin Pharmacol 1990; 30: 49-54.
134. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
135. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
136. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264: 3013-7.
137. Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997; 80: 111-5.
138. Malloy MJ, Kane JP, Kunitake ST, Tun P. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 1987; 107: 616-23.
139. Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 1999; 92: 387-94.
140. Kolovou GD, Dedoussis GV, Anagnostopoulou KK, Hatzigeorgiou G, Salpea KD, Choumerianou DM, et al. Management of a patient with a null low-density lipoprotein receptor mutation: A case report. Angiology 2006; 57: 729-32.
141. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29: 74-83.
142. Bays H, Abby S, Truitt K, Jones M. Colesevelam HCl reduces cholesterol and glucose levels when added to metformin-based therapy in patients with type 2 diabetes mellitus (Abstract). J Clin Lipidol 2007; 1: 505.
143. Jones M, Abby S, Truitt K. Colesevelam HCl is an effective and safe add-on to insulin-based therapy in patients with type 2 diabetes mellitus (Abstract). J Clin Lipidol 2007; 1: 504.
144. Ganda O, Abby S, Truitt K, Jones M. Colesevelam HCL is an effective and safe add-on to sulfonylurea-based therapy in patients with type 2 diabetes mellitus (abstract). J Clin Lipidol 2007; 1: 504.
145. Paraskevas KI, Mikhailidis DP. C-reactive protein (CRP): More than just an innocent bystander? Curr Med Res Opin 2008; 24: 75-8.
146. Devaraj S, Autret B, Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006; 98: 641-3.
147. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006; 97: 1198-205.
148. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
149. Hussein O, Frydman G, Frim H, Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after cholestyramine treatment in heterozygous familial hypercholesterolemic children. Pathophysiology 2001; 8: 21-28.
150. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004; 15: 251-8.
151. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53: 493-502.
152. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.
153. Simons LA, Sullivan D, Simons J, Celermajer DS. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 1998; 137: 197-203.
154. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336: 153-62.
155. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-12.
156. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005; 142: 95-104.
157. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: A systematic review. Arch Intern Med 2005; 165: 725-30.
158. A prospective, open label comparison of ezetimibe, niacin, and colestipol as adjunct therapy in lipid reduction. Available at http//www.clinicaltrials.gov/show/NCT00203476. Accessed at 13-04-08.
159. Zhao XQ, Phan BA, Chu B, Bray F, Moore AB, Polissar NL, et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: Study design of Carotid Plaque Composition Study. Am Heart J 2007; 154: 239-46.
160. Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus Not Previously Treated With Drug Therapy, and the Effects of Colesevelam HCl on Lipids and Glucose in Patients With Pre Diabetes. Available at http//www.clinicaltrials.gov/show/ NCT00570739. Accessed at 13-04-08.
161. Mechanisms of glucose lowering effect of colesevelam HCl. Available at http//www.clinicaltrials.gov/show/NCT00596427. Accessed at 13-04-08.
162. Effects of three drugs (colesevelam HCl, rosiglitazone, and ritagliptin) on control of blood glucose and lipids in patients with type 2 diabetes whose blood glucose is not completed controlled with metformin. Available at http//www.clinicaltrials.gov/show/ NCT00484419. Accessed at 13-04-08.
163. Effects of colesevelam HCl on bile acid kinetics. Available at http//www.clinicaltrials.gov/show/NCT00476710. Accessed at 13-04-08.
164. Nigro ND, Bhadrachari N, Chomchai C. A rat model for studying colonic cancer: Effect of cholestyramine on induced tumors. Dis Colon Rectum 1973; 16: 438-43.
165. Gallo DG, Bailey KR, Sheffner AL. The interaction between cholestyramine and drugs. Proc Soc Exp Biol Med 1965; 120: 60-5.
166. Neuvonen PJ, Kivisto K, Hirvisalo EL. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Br J Clin Pharmacol 1988; 25: 229-33.
167. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000; 14: 681-90.
168. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, Al-Saady N, Griffiths H, Hamilton G, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: Position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21: 959-69.
169. Toth PP, Davidson MH. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 455-62.
170. Altmann SW, Davis HR, Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
171. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005; 102: 8132-7.
172. Smart EJ, De Rose RA, Farber SA. Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc Natl Acad Sci U S A 2004; 101: 3450-5.
173. Kramer W, Girbig F, Corsiero D, Pfenninger A, Frick W, Jahne G, et al. Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J Biol Chem 2005; 280: 1306-20.
174. Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 2004; 47: 73-104.
175. Meng CQ. Ezetimibe (Schering-Plough). Curr Opin Investig Drugs 2001; 2: 389-92.
176. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, et al. Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins. Am J Cardiol 2008; 101: 490-6.
177. Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007; 63: 113-21.
178. Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005; 21: 333-8.
179. Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003; 25: 2352-87.
180. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-92.
181. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005; 37: 1033-5.
182. Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, et al. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: A post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther 2006; 28: 849-59.
183. Pearson TA, Denke MA, McBride PE, Battisti WP, Gazzara RA, Brady WE, et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: A substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 2006; 81: 1177-85.
184. Ness GC, Holland RC, Lopez D. Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption. Exp Biol Med (Maywood) 2006; 231: 559-65.
185. Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis 2005; 4: 16.
186. Simon JS, Karnoub MC, Devlin DJ, Arreaza MG, Qiu P, Monks SA, et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 2005; 86: 648-56.
187. Wang J, Joy T, Mymin D, Frohlich J, Hegele RA. Phenotypic heterogeneity of sitosterolemia. J Lipid Res 2004; 45: 2361-7.
188. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1092-7.
189. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8.
190. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies. Clin Ther 2001; 23: 1209-30.
191. Jurado J, Seip R, Thompson PD. Effectiveness of ezetimibe in clinical practice. Am J Cardiol 2004; 93: 641-3.
192. Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol 2008; 28: 1296-7.
193. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP. Management of high triglycerides: What non-specialists in lipids need to know. Hellenic J Cardiol 2005; 46: 268-72.
194. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729-41.
195. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003; 57: 363-8.
196. Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 2002; 62: 2333-47.
197. Al-Shaer MH. The effects of ezetimibe on the LDL-cholesterol particle number. Cardiovasc Drugs Ther 2004; 18: 327-8.
198. Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR. Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res 2006; 47: 2575-80.
199. Seedorf U, Engel T, Lueken A, Bode G, Lorkowski S, Assmann G. Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Commun 2004; 320: 1337-41.
200. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Targets for low-density lipoprotein cholesterol levels in patients with stable coronary heart disease: Where are we now after the "treating to new targets" (TNT) trial? Hellenic J Cardiol 2005; 46: 161-4.
201. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-91.
202. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-75.
203. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, et al. Efficacy and safety of ezetimibe coadministered with statins: Randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004; 58: 746-55.
204. Lipka L, Sager P, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004; 21: 1025-32.
205. Pearson GJ, Francis GA, Romney JS, Gilchrist DM, Opgenorth A, Gyenes GT. The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Can J Cardiol 2006; 22: 939-45.
206. Patel JV, Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract 2006; 60: 914-21.
207. Raal F, Schamroth C, Patel J, Becker P. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr 2007; 18: 325-9.
208. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007; 30: 230-5.
209. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterolassociated actions of ezetimibe: An overview. Expert Opin Ther Targets 2006; 10: 851-66.
210. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-34.
211. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004; 26: 1758-73.
212. Masana L, Mata P, Gagne C, Sirah W, Cho M, Johnson-Levonas AO, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo- controlled, 48-week extension study. Clin Ther 2005; 27: 174-84.
213. Feldman T, Koren M, Insull W, Jr., McKenney J, Schrott H, Lewin A, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481-6.
214. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620-9.
215. Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of coadministering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005; 102: 327-32.
216. Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005; 21: 571-8.
217. Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: Results of a pooled retrospective analysis. Curr Med Res Opin 2006; 22: 823-35.
218. Rodney RA, Sugimoto D, Wagman B, Zieve F, Kerzner B, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc 2006; 98: 772-8.
219. Cruz-Fernandez JM, Bedarida GV, Adgey J, Allen C, Johnson- Levonas AO, Massaad R. Efficacy and safety of ezetimibe coadministered with ongoing atorvastatin therapy in achieving lowdensity lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005; 59: 619-27.
220. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003; 107: 2409- 15.
221. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe coadministered with atorvastatin. Am Heart J 2004; 148: 447-55.
222. Reyderman L, Kosoglou T, Cutler DL, Maxwell S, Statkevich P. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Curr Med Res Opin 2005; 21: 1171-9.
223. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717-28.
224. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004; 20: 1185-95.
225. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418-24.
226. Kosoglou T, Statkevich P, Meyer I, Cutler DL, Musiol B, Yang B, et al. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin 2004; 20: 955-65.
227. Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. J Womens Health (Larchmt) 2004; 13: 1101-7.
228. Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson- Levonas AO, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005; 59: 1377-86.
229. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. Am J Cardiol 2008; 101: 483-5.
230. Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: A meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005; 21: 1123-30.
231. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006; 22: 2041-53.
232. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins. Cardiovasc Diabetol 2006; 5: 20.
233. Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004; 20: 1437-45.
234. Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: Results of the EASEGO study. Curr Med Res Opin 2008; 24: 685-94.
235. Constance C, Westphal S, Chung N, Lund M, McCrary Sisk C, Johnson-Levonas AO, et al. Efficacy of ezetimibe/simvastatin 10/ 20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*. Diabetes Obes Metab 2007; 9: 575-84.
236. Constance C, Westphal S, Chung N, Lund M, McCrary Sisk C, Johnson-Levonas AO, et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9: 575-84.
237. Hildemann SK, Barho C, Karmann B, Darius H, Bestehorn K. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: Prospective observational cohort studies in clinical practice. Curr Med Res Opin 2007; 23: 713-9.
238. Simons LA, Symons J. Ezetimibe added to statin therapy (EASY study) - an evaluation by Australian general practitioners. Aust Fam Physician 2007; 36: 90-2, 96.
239. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: The VYTAL study. Mayo Clin Proc 2006; 81: 1579-88.
240. Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005; 7: 88-97.
241. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 2006; 3: 93-102.
242. Yamamoto A, Harada-Shiba M, Endo M, Kusakabe N, Tanioka T, Kato H, et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis 2006; 186: 126-31.
243. Lind S, Olsson AG, Eriksson M, Rudling M, Eggertsen G, Angelin B. Autosomal recessive hypercholesterolaemia: Normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med 2004; 256: 406-12.
244. Rodenburg J, Wiegman A, Vissers MN, Kastelein JJ, Stalenhoef AF. A boy with autosomal recessive hypercholesterolaemia. Neth J Med 2004; 62: 89-93.
245. Hendriksz CJ, Norbury G, Tabrah S, Taylor A, Humphries SE. Homozygous hypercholesterolaemia and ezetimibe: A case report. Acta Paediatr 2004; 93: 280-2.
246. Geiss HC, Otto C, Hund-Wissner E, Parhofer KG. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis 2005; 180: 107-12.
247. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487-94.
248. Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am J Geriatr Pharmacother 2005; 3: 218-28.
249. Kalogirou M, Tsimihodimos V, Saougos V, Lagos K, Tselepis A, Elisaf M. Effect of ezetimibe on lipoprotein subfraction concentrations: The role of atorvastatin pretreatment. Arch Med Sci 2007; 3: 344-350.
250. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
251. Sampalis JS, Bissonnette S, Habib R, Boukas S. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. Ann Pharmacother 2007; 41: 1345-51.
252. Meyers CD, Moon YS, Ghanem H, Wong ND. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe. Ann Pharmacother 2006; 40: 818-23.
253. Gouni-Berthold I, Berthold HK, Gylling H, Hallikainen M, Giannakidou E, Stier S, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMGCoA reductase gene expression: A randomized trial in healthy men. Atherosclerosis 2008; 198: 198-207.
254. Ziajka PE, Reis M, Kreul S, King H. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am J Cardiol 2004; 93: 779-80
255. Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: An exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007; 29: 2419-32.
256. Geiss HC, Otto C, Parhofer KG. Effect of ezetimibe on low-density lipoprotein subtype distribution: Results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism 2006; 55: 599-604.
257. Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905.
258. McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47: 1584-7.
259. Kosoglou T, Statkevich P, Fruchart JC, Pember LJ, Reyderman L, Cutler DL, et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004; 20: 1197-207.
260. Chan DC, Chen MM, Ooi EM, Watts GF. An ABC of apolipoprotein C-III: A clinically useful new cardiovascular risk factor? Int J Clin Pract 2008: 62: 799-809.
261. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008; 51: 1564-72.
262. Jelesoff NE, Ballantyne CM, Xydakis AM, Chiou P, Jones PH, Guyton JR. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract 2006; 12: 159-64.
263. Jakulj L, Trip MD, Sudhop T, von Bergmann K, Kastelein JJ, Vissers MN. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: Effects on plasma lipid levels. J Lipid Res 2005; 46: 2692-8.
264. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008; 24: 1919-29.
265. Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, Hernandez-Salazar E, Ramos-Zavala MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther 2006; 20: 143-6.
266. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005; 280: 12710-20.
267. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study. Curr Med Res Opin 2006; 22: 873-83.
268. Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007; 42: 139-47.
269. Hughes EA, Tracey I, Singhal S, Patel J. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. Med Hypotheses 2006; 67: 1463-4.
270. Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med Hypotheses 2006; 66: 844-6.
271. Zheng S, Hoos L, Cook J, Tetzloff G, Davis H, Jr., van Heek M, et al. Ezetimibe improves high fat and cholesterol diet-induced nonalcoholic fatty liver disease in mice. Eur J Pharmacol 2008; 584: 118-24.
272. Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 4369-76.
273. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-70
274. van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001; 134: 409-17.
275. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006; 47: 385-95.
276. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
277. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
278. Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007; 22: 963-4.
279. Athyros VG, Karagiannis A, Liberopoulos EN, Elisaf M, Mikhailidis DP. Statin treatment may be beneficial to both the kidneys and the heart. Perit Dial Int 2007; 27: 215-6.
280. Turk TR, Voropaeva E, Kohnle M, Nurnberger J, Philipp T, Kribben A, et al. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: A pilot study. Nephrol Dial Transplant 2008; 23: 369-373.
281. Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006; 6: 205-8.
282. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006; 6: 770-4.
283. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 2006; 81: 804-7.
284. Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50: 852-8.
285. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-63.
286. Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mugge A, Spiecker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome - effect of different lipid-lowering regimens. Cardiology 2005; 104: 176-80.
287. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: Clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006; 27: 1182-90.
288. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003; 92: 1414-8.
289. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005; 179: 361-7.
290. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-73.
291. Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: The INFORCE study. Int J Clin Pract 2008; 62: 539-54.
292. Panichi V, Manca-Rizza G, Paoletti S, Taccola D, Consani C, Sbragia G, et al. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: A pilot study. Biomed Pharmacother 2006; 60: 249-52.
293. Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002; 7: 219-26.
294. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004; 9: 27-33.
295. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18: 269-76.
296. Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: Potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3: 57-68.
297. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15: 1764-73.
298. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42.
299. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation 2005; 111: 570-5.
300. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27: 2236-43.
301. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008; 68: 536-41.
302. Derdemezis C, Filippatos T, Tselepis A, Mikhailidis D, Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: A pilot study. Expert Opin Pharmacother 2008; 9: 1829-37.
303. Assmann G, Cullen P, Erbey J, Ramey DR, Kannenberg F, Schulte H. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: Results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovasc Dis 2006; 16: 13-21.
304. Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004; 109: 966-71.
305. Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin 2008; 24: 249-59.
306. Sudhop T, Lutjohann D, von Bergmann K. Sterol transporters: Targets of natural sterols and new lipid lowering drugs. Pharmacol Ther 2005; 105: 333-41.
307. von Bergmann K, Sudhop T, Lutjohann D. Cholesterol and plant sterol absorption: Recent insights. Am J Cardiol 2005; 96: 10D-14D.
308. Nikkila K, Miettinen TA, Hockerstedt KV, Isoniemi H. Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation. Transpl Int 2005; 18: 221-5.
309. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33: 226-9.
310. Miyake Y, Shouzu A, Nishikawa M, Yonemoto T, Shimizu H, Omoto S, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999; 49: 324-9.
311. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: A randomised trial. Drug Saf 2006; 29: 703-12.
312. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80: 587-95.
313. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-80.
314. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
315. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358: 1504-7.
316. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med 2008; 358: 1507-8.
317. Stein EA. After ENHANCE: Is more LDL cholesterol lowering even better? Clin Chem 2008; 54: 940-2.
318. van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005; 95: 264-6.
319. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT. Available at http//www.clinicaltrials.gov/show/ NCT00202878. Accessed at 13-04-08.
320. Rossebo AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007; 99: 970-3.
321. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003: S207-10.
322. Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS). Cardiovasc Drugs Ther 2007; 21: 221-5.
323. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Available at http//www.clinicaltrials.gov/show/ NCT00461630. Accessed at 13-04-08.
324. Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients (REVIERTE). Available at http//www.clinicaltrials.gov/ show/NCT00621127. Accessed at 13-04-08.
325. The influence of ezetimibe on gallbladder function. Available at http//www.clinicaltrials.gov/show/NCT00634140. Accessed at 13-04-08.
326. Evaluation of chylomicrons metabolism in sub-clinical atherosclerosis in patients whit Heterozigous Familial Hypercholesterolemia (FH) treated with statin plus ezetimibe. Available at http//www.clinicaltrials.gov/ show/NCT00475826. Accessed at 13-04-08.
327. A multicenter, randomized, double-blind, parallel arm, 12-week study to evaluate the efficacy and safety of ezetimibe 10 mg when added to atorvastatin 10 mg vs titration to atorvastatin 20 mg and to 40 mg in elderly patients with hypercholesterolemia at high risk for CHD. Available at http//www.clinicaltrials.gov/show/NCT00418834. Accessed at 13-04-08.
328. A multicenter, randomized, double-blind, titration study to evaluate and compare the efficacy & safety of ezetimibe plus atorvastatin vs atorvastatin in hypercholesterolaemic patients at moderately high risk for CHD not adequately controlled on atorvastatin 20 mg. Available at http//www.clinicaltrials.gov/show/NCT00276458. Accessed at 13-04-08.
329. Effects of statin and ezetimibe association on kinetics of artificial chilomicrons in men with stable coronary heart disease. Available at http//www.clinicaltrials.gov/show/NCT00481351. Accessed at 13-04-08.
330. Effects of ezetimibe add-on to statin therapy on adipokine production in obese and MetS patients with atherosclerosis. Available at http//www.clinicaltrials.gov/show/NCT00485121. Accessed at 13-04-08.
331. Randomized, double-blind, active-controlled, multicenter study to assess the LDL-C lowering of switching to a combo tab ezetimibe/simvastatin (10 mg/20 mg) compared to rosuvastatin 10 mg in patients with primary high cholesterol and high CVD risk not controlled with a prior statin treatment. Available at http//www.clinicaltrials.gov/show/NCT00479713. Accessed at 13-04-08.
332. Multicenter, randomized, double-blind, parallel, 12-week study to evaluate the efficacy and safety of ezetimibe/simvastatin combination tablet vs atorvastatin in elderly patients with hypercholesterolemia at high or moderately high risk for CHD. Available at http//www.clinicaltrials.gov/show/NCT00535405. Accessed at 13-04-08.
333. Multicenter, randomized, double-blind, parallel arm, 6-week study to evaluate the efficacy and safety of ezetimibe/simvastatin vs atorvastatin in patients with metabolic syndrome and hypercholesterolemia at high risk for CHD. Available at http//www.clinicaltrials.gov/show/NCT00409773. Accessed at 13-04-08.
334. Vascular Effects of Ezetimibe/Simvastatin and Simvastatin on Atherosclerosis. Available at http//www.clinicaltrials.gov/show/ NCT00560170. Accessed at 13-04-08.
335. Effect of ezetimibe on flow-mediated brachial artery reactivity in healthy subjects. Available at http//www.clinicaltrials.gov/show/ NCT00376246. Accessed at 13-04-08.
336. A 12-week open-label, randomised, parallel-group, multicentre study to compare the efficacy and safety of rosuvastatin in combination with ezetimibe and simvastatin in patients with hypercholesterolaemia and CHD. Available at http//www.clinicaltrials.gov/show/NCT00525824. Accessed at 13-04-08.
337. Atorvastatin vs ezetimibe and fenofibrate as a lipid-lowering strategy. Available at http//www.clinicaltrials.gov/show/NCT00299884. Accessed at 13-04-08.
338. Primary Care Study. Available at http//www.clinicaltrials.gov/ show/NCT00462748. Accessed at 13-04-08.
339. A study evaluating the effects of lipid lowering treatment on steroi synthesis. Available at http//www.clinicaltrials.gov/show/NCT00 433823. Accessed at 13-04-08.
340. A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea. Available at http//www.clinicaltrials.gov/show/NCT00496730. Accessed at 13-04-08.
341. Clinical trial of Zocor and Vytorin in adolescents with type 1 diabetes. Available at http//www.clinicaltrials.gov/show/NCT00477204. Accessed at 13-04-08.
342. Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004; 58: 653-8.
343. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: What the clinician needs to know. Int J Clin Pract 2008; 62: 88-96.
344. Havranek JM, Wolfsen AR, Warnke GA, Phillips PS. Monotherapy with ezetimibe causing myopathy. Am J Med 2006; 119: 285-6.
345. Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006; 22: 141-4.
346. Perez-Calvo J, Civeira-Murillo F, Cabello A. Worsening myopathy associated with ezetimibe in a patient with McArdle disease. QJM 2005; 98: 461-2.
347. Phillips PS. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004; 141: 649.
348. Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006; 97: 223-8.
349. Fux R, Morike K, Gundel UF, Hartmann R, Gleiter CH. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004; 140: 671-2.
350. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467-94.
351. van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 2005; 42: 402-4.
352. Stolk MF, Becx MC, Kuypers KC, Seldenrijk CA. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol 2006; 4: 908-11.
353. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: Dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006; 22: 511-28.
354. Reyderman L, Kosoglou T, Boutros T, Seiberling M, Statkevich P. Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Curr Med Res Opin 2004; 20: 1493-500.
355. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54: 309-19.
356. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 2006; 46: 328-36.
357. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol 2006; 46: 321-.
358. Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005; 39: 1561-5.
359. John S, Sorokin AV, Thompson PD. Phytosterols and vascular disease. Curr Opin Lipidol 2007; 18: 35-40.
360. Ortega RM, Palencia A, Lopez-Sobaler AM. Improvement of cholesterol levels and reduction of cardiovascular risk via the consumption of phytosterols. Br J Nutr 2006; 96 Suppl 1: S89-93.
361. Law M. Plant sterol and stanol margarines and health. BMJ 2000; 320: 861-4.
362. Perisee DM. Food fortification with plant sterol/stanol for hyperlipidemia: Management in free-living populations. J Am Diet Assoc 2005; 105: 52-3.
363. Ostlund RE, Jr. Phytosterols and cholesterol metabolism. Curr Opin Lipidol 2004; 15: 37-41.
364. Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res 2000; 41: 697-705
365. Marinangeli CP, Varady KA, Jones PJ. Plant sterols combined with exercise for the treatment of hypercholesterolemia: Overview of independent and synergistic mechanisms of action. J Nutr Biochem 2006; 17: 217-24.
366. Plosch T, Kruit JK, Bloks VW, Huijkman NC, Havinga R, Duchateau GS, et al. Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5/8 transporter. J Nutr 2006; 136: 2135-40.
367. Ostlund RE, Jr. Phytosterols, cholesterol absorption and healthy diets. Lipids 2007; 42: 41-5.
368. McPherson TB, Ostlund RE, Goldberg AC, Bateman JH, Schimmoeller L, Spilburg CA. Phytostanol tablets reduce human LDL-cholesterol. J Pharm Pharmacol 2005; 57: 889-96.
369. Cleghorn CL, Skeaff CM, Mann J, Chisholm A. Plant sterol-enriched spread enhances the cholesterol-lowering potential of a fat-reduced diet. Eur J Clin Nutr 2003; 57: 170-6.
370. Plana N, Nicolle C, Ferre R, Camps J, Cos R, Villoria J, et al. Plant sterol-enriched fermented milk enhances the attainment of LDL-cholesterol goal in hypercholesterolemic subjects. Eur J Nutr 2008.
371. Chan YM, Demonty I, Pelled D, Jones PJ. Olive oil containing olive oil fatty acid esters of plant sterols and dietary diacylglycerol reduces low-density lipoprotein cholesterol and decreases the tendency for peroxidation in hypercholesterolaemic subjects. Br J Nutr 2007; 98: 563-70.
372. Acuff RV, Cai DJ, Dong ZP, Bell D. The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects. Lipids Health Dis 2007; 6: 11.
373. Shrestha S, Volek JS, Udani J, Wood RJ, Greene CM, Aggarwal D, et al. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr 2006; 136: 2492-7.
374. Goncalves S, Maria AV, Silva AS, Martins-Silva J, Saldanha C. Phytosterols in milk as a depressor of plasma cholesterol levels: experimental evidence with hypercholesterolemic Portuguese subjects. Clin Hemorheol Microcirc 2006; 35: 251-5.
375. Jenkins DJ, Kendall CW, Faulkner DA, Nguyen T, Kemp T, Marchie A, et al. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Am J Clin Nutr 2006; 83: 582-91.
376. Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: A systematic review with meta-analysis. J Am Coll Nutr 2006; 25: 41-8
377. Lau VW, Journoud M, Jones PJ. Plant sterols are efficacious in lowering plasma LDL and non-HDL cholesterol in hypercholesterolemic type 2 diabetic and nondiabetic persons. Am J Clin Nutr 2005; 81: 1351-8.
378. Patch CS, Tapsell LC, Williams PG. Plant sterol/stanol prescription is an effective treatment strategy for managing hypercholesterolemia in outpatient clinical practice. J Am Diet Assoc 2005; 105: 46-52.
379. Castro IA, Barroso LP, Sinnecker P. Functional foods for coronary heart disease risk reduction: A meta-analysis using a multivariate approach. Am J Clin Nutr 2005; 82: 32-40.
380. Amundsen AL, Ntanios F, Put N, Ose L. Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread. Eur J Clin Nutr 2004; 58: 1612-20.
381. Thomsen AB, Hansen HB, Christiansen C, Green H, Berger A. Effect of free plant sterols in low-fat milk on serum lipid profile in hypercholesterolemic subjects. Eur J Clin Nutr 2004; 58: 860-70.
382. Normen L, Holmes D, Frohlich J. Plant sterols and their role in combined use with statins for lipid lowering. Curr Opin Investig Drugs 2005; 6: 307-16.
383. Hallikainen MA, Sarkkinen ES, Gylling H, Erkkila AT, Uusitupa MI. Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet. Eur J Clin Nutr 2000; 54: 715-25.
384. Clifton PM, Noakes M, Sullivan D, Erichsen N, Ross D, Annison G, et al. Cholesterol-lowering effects of plant sterol esters differ in milk, yoghurt, bread and cereal. Eur J Clin Nutr 2004; 58: 503-9.
385. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000; 86: 46-52.
386. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 1997; 96: 4226-31.
387. Thompson GR. Additive effects of plant sterol and stanol esters to statin therapy. Am J Cardiol 2005; 96: 37D-39D.
388. Goldberg AC, Ostlund RE, Jr., Bateman JH, Schimmoeller L, McPherson TB, Spilburg CA. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol 2006; 97: 376-9.
389. Kozlowska-Wojciechowska M, Jastrzebska M, Naruszewicz M, Foltynska A. Impact of margarine enriched with plant sterols on blood lipids, platelet function, and fibrinogen level in young men. Metabolism 2003; 52: 1373-8.
390. Homma Y, Ikeda I, Ishikawa T, Tateno M, Sugano M, Nakamura H. Decrease in plasma low-density lipoprotein cholesterol, apolipoprotein B, cholesteryl ester transfer protein, and oxidized low-density lipoprotein by plant stanol ester-containing spread: A randomized, placebo-controlled trial. Nutrition 2003; 19: 369-74.
391. Naruszewicz M, Kozlowska-Wojciechowska M. Plant sterols beyond low-density lipoprotein-cholesterol. Br J Nutr 2007; 98: 454-5.
392. Effect of plant sterols esterified to fish oil fatty acids on plasma lipid levels. Available at http//www.clinicaltrials.gov/show/ NCT00441480. Accessed at 13-04-08.
393. Effect of plant sterol supplement on blood cholesterol. Available at http//www.clinicaltrials.gov/show/NCT00485095. Accessed at 13-04-08.
394. Effects of a long term dietary portfolio and of sequential removal of food components from the diet. Available at http//www.clinicaltrials.gov/show/NCT00438893. Accessed at 13-04-08.
395. Portfolio 5 - Multicentre. Available at http//www.clinicaltrials.gov/ show/NCT00438425. Accessed at 13-04-08.
396. Clifton PM, Noakes M, Ross D, Fassoulakis A, Cehun M, Nestel P. High dietary intake of phytosterol esters decreases carotenoids and increases plasma plant sterol levels with no additional cholesterol lowering. J Lipid Res 2004; 45: 1493-9.
397. Davidson MH, Maki KC, Umporowicz DM, Ingram KA, Dicklin MR, Schaefer E, et al. Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J Am Coll Nutr 2001; 20: 307-19.
398. Gylling H, Miettinen TA. The effect of plant stanol- and sterol-enriched foods on lipid metabolism, serum lipids and coronary heart disease. Ann Clin Biochem 2005; 42: 254-63.
399. Gylling H, Puska P, Vartiainen E, Miettinen TA. Serum sterols during stanol ester feeding in a mildly hypercholesterolemic population. J Lipid Res 1999; 40: 593-600.
400. Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY. Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr 2003; 57: 681-92.
401. Weingartner O, Lutjohann D, Ji S, Weisshoff N, List F, Sudhop T, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol 2008; 51: 1553-61.
402. Pinedo S, Vissers MN, von Bergmann K, Elharchaoui K, Lutjohann D, Luben R, et al. Plasma levels of plant sterols and the risk of coronary artery disease: The prospective EPIC-Norfolk Population Study. J Lipid Res 2007; 48: 139-44.
403. Fassbender K, Lutjohann D, Dik MG, Bremmer M, Konig J, Walter S, et al. Moderately elevated plant sterol levels are associated with reduced cardiovascular risk - the LASA study. Atherosclerosis 2008; 196: 283-8.
404. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21 (Suppl 3): S12-23.
405. Carriere F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato F, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001; 281: G16-28.
406. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 2007; 335: 1194-9.
407. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002; 20: 2257-67
408. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-21.
409. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003; 91: 961-4.
410. Micic D, Ivkovic-Lazar T, Dragojevic R, Jorga J, Stokic E, Hajdukovic Z. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Med Pregl 1999; 52: 323-33.
411. Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004; 4: 63-8.
412. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136-41.
413. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004; 25: 342-8.
414. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87: 827-31.
415. Bray G, Torgerson J, Sjostrom L, Boldrin M, Hauptman J. Effect of orlistat in obese patients with the metabolic syndrome as defined by the NCEP (ATPIII). Diabetes 2003; 52 (Suppl 1): A392.
416. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-94.
417. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-8.
418. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033-41.
419. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31: 15-22.
420. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. Jama 1999; 281: 235-42.
421. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-72.
422. Mittendorfer B, Ostlund RE, Jr., Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001; 9: 599-604.
423. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008; 10: 476-83.
424. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003; 5: 180-8.
425. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415-23.
426. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49-61.
427. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49-55.
428. Petrogiannopoulos C, Kalogeropoulos S, Latsios GS, Hartzoulakis G, Kalogeropoulos G, Zaharof A. Orlistat use in overweight women with mild hypercholesterolemia. Int J Clin Pharmacol Res 2002; 22: 85-8.
429. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003; 25: 1107-22.
430. Filippatos T, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari E, Kiortsis D, et al. Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol 2008; In press.
431. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 428-37.
432. Derosa G, Mugellini A, Ciccarelli L, Rinaldi A, Fogari R. Effects of Orlistat, Simvastatin and Orlistat+Simvastatin in Obese Patients with Hypercholesterolemia: A Randomised, Open-Label Trial. Curr Ther Res Clin Exp 2002; 63: 621-633.
433. Derosa G, Mugellini A, Fogari R. Comparison between diet, orlistat and cerivastatin in hypercholesterolemic, obese patients, with mild hypertension [Abstract]. Atherosclerosis Supplements 2001; 2: 93.
434. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: The FenOrli study. Curr Med Res Opin 2005; 21: 1997-2006.
435. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-6.
436. Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002; 162: 2428-35.
437. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61
438. Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001; 25: 212-8.
439. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab 2003; 5: 195-201.
440. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-4.
441. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-44.
442. Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007; 56: 443-4.
443. Filippatos TD, Derdemezis CS, Georgoula M, Kiortsis DN, Tselepis AD, Elisaf MS. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J Med Sci Res 2007; 2: 9-10.
444. Randomized clinical trial of metformin vs orlistat in obese anovulatory women. Available at http//www.clinicaltrials.gov/show/NCT00292799. Accessed at 13-04-08.
445. Study for the treatment of significant steatosis with Xenical followed by treatment of hepatitis C with Pegasys/Copegus. Available at http//www.clinicaltrials.gov/show/NCT00207311. Accessed at 13-04-08.
446. The Effect of Xenical on Weight and Risk Factors. Available at http//www.clinicaltrials.gov/show/NCT00152360. Accessed at 13-04-08.
447. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: A critical review. Drug Saf 2008; 31: 53-65.
448. Chen L, Rogers SL, Colagiuri S, Cadilhac DA, Mathew TH, Boyden AN, et al. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the Aus-Diab Study, 1999-2000. Med J Aust 2008; 189(6): 319-322.
449. Corcoran BM, Stanton C, Fitzgerald G, Ross RP. Life under stress: The probiotic stress response and how it may be manipulated. Curr Pharm Des 2008; 14(14): 1382-99.
450. Paraskevas KI, Mikhailidis DP, Thompson CS. Experimental models for the study of drugs used to prevent and treat vascular diseases. Curr Pharm Des 2008; 14(4): 306-8.